Journal of Zhejiang University SCIENCE B

, Volume 13, Issue 9, pp 745–750 | Cite as

Topical imiquimod treatment of cutaneous vascular disorders in pediatric patients: clinical evaluation on the efficacy and safety

Article

Abstract

Objective

To evaluate the clinical effect of topical imiquimod treatment on cutaneous vascular disorders in pediatric patients.

Methods

A retrospective investigation was conducted in 25 pediatric patients with cutaneous vascular disorders, including 19 infantile hemangiomas (IHs) (12 superficial/7 mixed type), 5 nevus flammeus (NF), and 1 pyogenic granuloma (PG). Imiquimod 5% cream was applied every other day for 4 to 16 weeks (average 9.6 weeks).

Results

Of the 19 IHs treated, an overall efficacy of 52.6% was achieved, with a clinical resolution rate of 15.8%, excellent rate of 26.3%, and moderate rate of 10.5%. The superficial type responded the best at 66.7%, while the mixed type showed only 28.6% effectiveness, which was predominantly from their superficial parts. No obvious response was noted in the 5 patients with NF. Side effects were observed in 78.9% of the patients, mostly mild to moderate local irritations and occasionally severe reactions such as thick crusting and ulceration. Systemic side events were observed in 4 IH patients including fever and digestive tract reactions. No recurrence was observed during the follow-up examination.

Conclusions

Topical imiquimod could be an alternative option for the treatment of uncomplicated superficial IHs with satisfactory tolerability.

Key words

Infantile hemangioma (IH) Nevus flammeus (NF) Imiquimod Treatment 

CLC number

R751.05 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barry, R.B., Hughes, B.R., Cook, L.J., 2008. Involution of infantile haemangiomas after imiquimod 5% cream. Clin. Exp. Dermatol., 33(4):446–449. [doi:10.1111/j.1365-2230.2007.02676.x]PubMedCrossRefGoogle Scholar
  2. Brouty-Boyé, D., Zetter, B.R., 1980. Inhibition of cell motility by interferon. Science, 208(4443):516–518. [doi:10.1126/science.6154315]PubMedCrossRefGoogle Scholar
  3. Bruckner, A.L., Frieden, I.J., 2006. Infantile Hemangiomas. J. Am. Acad. Dermatol., 55(4):671–682. [doi:10.1016/j.jaad. 2006.05.017]PubMedCrossRefGoogle Scholar
  4. Duda, D.G., Sunamura, M., Lozonschi, L., Kodama, T., Egawa, S., Matsumoto, G., Shimamura, H., Shibuya, K., Takeda, K., Matsuno, S., 2000. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res., 60(4):1111–1116.PubMedGoogle Scholar
  5. Guo, Z., Li, G., Xu, Q., Gao, Y., Li, P., Zhang, X., Duan, Y., Guo, X., Zheng, B., 2009. Clinical observations on the treatment of infantile hemangiomas with topical imiquimod 5% cream. J. Nanjing Med. Univ., 23(3):177–182. [doi:10.1016/S1007-4376(09)60051-4]CrossRefGoogle Scholar
  6. Hazen, P.G., Carney, J.F., Engstrom, C.W., Turgeon, K.L., Reep, M.D., Tanphaichitr, A., 2005. Proliferating haemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr. Dermatol., 22(3):254–256. [doi:10.1111/j.1525-1470.2005.22318.x]PubMedCrossRefGoogle Scholar
  7. Ho, N.T., Lansang, P., Pope, E., 2007. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J. Am. Acad. Dermatol., 56(1):63–68. [doi:10.1016/j.jaad.2006.06.011]PubMedCrossRefGoogle Scholar
  8. Li, V.W., Li, W.W., Talcott, K.E., Zhai, A.W., 2005. Imiquimod as an antiangiogenic agent. J. Drugs Dermatol., 4(6):708–717.PubMedGoogle Scholar
  9. Martinez, M.I., Sanchez-Carpintero, I., North, P.E., Mihm, M.C.Jr., 2002. Infantile haemangioma: clinical resolution with 5% imiquimod cream. Arch. Dermatol., 138(7): 881–884. [doi:10.1001/archderm.138.7.881]PubMedCrossRefGoogle Scholar
  10. McCuaig, C.C., Dubois, J., Powell, J., Belleville, C., David, M., Rousseau, E., Gendron, R., Jafarian, F., Auger, I., 2009. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr. Dermatol., 26(2):203–212. [doi:10.1111/j.1525-1470.2008.00857.x]PubMedCrossRefGoogle Scholar
  11. Musumeci, M.L., Schlecht, K., Perrotta, R., Schwartz, R.A., Micali, G., 2008. Management of cutaneous hemangiomas in pediatric patients. Cutis, 81(4):315–322.PubMedGoogle Scholar
  12. Sanchez-Carpintero, I., Martínez, M.I., Mihm, M.C.Jr., 2006. Clinical and histopathologic observations of the action of imiquimod in an epithelioid hemangioendothelioma and Paget’s mammary disease. J. Am. Acad. Dermatol., 55(1): 75–79. [doi:10.1016/j.jaad.2006.01.056]PubMedCrossRefGoogle Scholar
  13. Sidbury, R., Neuschler, N., Neuschler, E., Sun, P., Wang, X., Miller, R., Tomai, M., Puscasiu, E., Gugneja, S., Paller, A.S., 2003. Topically applied imiquimod inhibits vascular tumor growth in vivo. J. Invest. Dermatol., 121(5): 1205–1209. [doi:10.1046/j.1523-1747.2003.12521.x]PubMedCrossRefGoogle Scholar
  14. Sidky, Y.A., Borden, E.C., 1987. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res., 47(19):5155–5161.PubMedGoogle Scholar
  15. Stanley, M.A., 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol., 27(7):571–577. [doi:10.1046/j.1365-2230. 2002.01151.x]PubMedCrossRefGoogle Scholar
  16. Sun, Z.J., Zhao, Y.F., Zhang, W.F., 2007. Immune response: a possible role in the pathophysiology of hemangioma. Med. Hypotheses, 68(2):353–355. [doi:10.1016/j.mehy.2006.07.013]PubMedCrossRefGoogle Scholar
  17. van Seters, M., van Beurden, M., ten Kate, F.J., Beckmann, I., Ewing, P.C., Eijkemans, M.J., Kagie, M.J., Meijer, C.J., Aaronson, N.K., Kleinjan, A., et al., 2008. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N. Engl. J. Med., 358(14):1465–1473. [doi:10.1056/NEJMoa 072685]PubMedCrossRefGoogle Scholar
  18. Wang, C., Quevedo, M.E., Lannutti, B.J., Gordon, K.B., Guo, D., Sun, W., Paller, A.S., 1999. In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. J. Invest. Dermatol., 112(5):775–781. [doi:10.1046/j.1523-1747.1999. 00587.x]PubMedCrossRefGoogle Scholar
  19. Wang, J.Y., Liu, L.F., Mao, X.H., 2012. Treatment of lymphangioma circumscriptum with topical imiquimod 5% cream. Dermatol. Surg., in press. [doi:10.1111/j.1524-4725.2012.02528.x]Google Scholar
  20. Welsh, O., Olazarán, Z., Gómez, M., Salas, J., Berman, B., 2004. Treatment of infantile haemangiomas with short-term application of imiquimod 5% cream. J. Am. Acad. Dermatol., 51(4):639–642. [doi:10.1016/j.jaad. 2004.04.022]PubMedCrossRefGoogle Scholar

Copyright information

© Zhejiang University and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Dermatology, the Second Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations